{"id":"W3003197239","doi":"10.3389/fonc.2020.00066","title":"Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial","year":2020,"lang":"en","type":"letter","venue":"Frontiers in Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Hospital; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Temozolomide; Lomustine; Medicine; Glioblastoma; Oncology; Internal medicine; Open label; O-6-methylguanine-DNA methyltransferase; Bevacizumab; Dacarbazine; Progression-free survival; Randomized controlled trial; Chemotherapy; Cancer research; Methylation; Methyltransferase; Vincristine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006313524,0.00127729,0.002064482,0.0008064148,0.002665889,0.002039434,0.002967876,0.04409199,0.01340456],"category_scores_gemma":[0.02958666,0.0007166721,0.001717873,0.001145417,0.001619012,0.002346006,0.0009516576,0.02532598,0.01464647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005339755,"about_ca_system_score_gemma":0.005631368,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007016017,"about_ca_topic_score_gemma":0.0102917,"domain_scores_codex":[0.9966103,0.001428971,0.0004039225,0.0004363122,0.0008087202,0.0003116476],"domain_scores_gemma":[0.9869066,0.007759154,0.0009638559,0.0002363193,0.002549062,0.001584915],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0002310009,0.00001781617,0.00009138722,0.0001266527,0.0000158283,0.0001690819,0.00002491965,0.00002931398,0.00007286567,0.0003273398,0.9945141,0.004379692],"study_design_scores_gemma":[0.00143969,0.000372681,0.001471715,0.001070434,0.000173538,0.0008983274,0.0001737898,0.0005006943,0.0004417642,0.007035751,0.9863207,0.0001009398],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0003632809,0.001967777,0.00007453443,0.9442798,0.04999203,0.00005711364,0.0007622549,0.00007049446,0.002432705],"genre_scores_gemma":[0.002832566,0.001360055,0.0002075177,0.9273556,0.06055602,0.0001635629,0.0002032394,0.00004138086,0.007280181],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.04409199,"threshold_uncertainty_score":0.04484266,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02732472459292446,"score_gpt":0.3146874924040877,"score_spread":0.2873627678111633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}